Specialist doctors from across the globe participated in the symposium, organised at Rajiv Gandhi Cancer Institute and Research Centre (RGCI&RC).
The technique of theranostics is a combination of diagnostics and therapy, which offers personalised accurate treatment for prostate cancer and neuroendocrine tumors, said Dr Partha S Choudhury, Director, Nuclear Medicine, RGCI&RC.
"The field of theranostics is rapidly facilitating the shift from 'trial and error' medicine to personalised medicine and holds great promise for improved patient outcomes," he said.
Delegates of the symposium were given detailed insight into the specific receptor based imaging of neuroendocrine and prostate tumors in diagnosis, evaluation of treatment response and prognosis during the event, he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
